-
Cleave is developing small molecules against new targets that regulate protein homeostasis and might be able to treat a wider range of cancers than proteasome inhibitors.
Published on 3/25/2013
-
Labrys: Navigating migraine Labrys Biologics Inc. San Mateo, Calif. Technology: mAb against calcitonin gene-related peptide (CGRP) for migraine Disease focus: Neurology Clinical status: Completed Phase I Founded…
Published on 3/25/2013
-
Labrys is reviving development of RN-307, a former Pfizer mAb that the biotech is positioning to prevent migraine attacks in patients who have progressed to chronic disease.
Published on 3/25/2013
-
Acesion: Accessing SK in AF Acesion Pharma ApS Copenhagen, Denmark Technology: SK channel inhibitors Disease focus: Cardiovascular Clinical status: Discovery Founded: 2011 by Ulrik Sorensen and Morten Grunnet …
Published on 3/18/2013
-
The specificity of Acesion's SK channel inhibitors could provide a safety advantage over drugs marketed for atrial fibrillation.
Published on 3/18/2013
-
Colonoscopy comfort gIcare pharma Inc. Montreal, Quebec Technology: Colonic analgesic compounds that release hydrogen sulfide Disease focus: Neurology Clinical status: Phase I Founded: 2011 by Maxime Ranger and …
Published on 3/18/2013
-
gIcare is developing a pipeline of non-sedating colonic analgesic compounds to provide new, lower cost alternatives for pain management during colonoscopy.
Published on 3/18/2013
-
Blackfield: Mining cancer genomes Blackfield AG Cologne, Germany Technology: Cancer genome analysis and target discovery Disease focus: Cancer, genomics Clinical status: Discovery Founded: 2012 by Axel Ullrich, …
Published on 3/11/2013
-
Blackfield is leveraging the genome analysis experience and oncology expertise of its academic founders to offer a one-stop shop for cancer genomics-based drug discovery services.
Published on 3/11/2013
-
FPRT Bio: Neutralizing neuroinflammation FPRT Bio Inc. Scranton, Pa. Technology: Mimic of soluble TNF to treat neurodegenerative diseases Disease focus: Neurology Clinical status: Preclinical Founded: 2012 by …
Published on 3/11/2013
-
FPRT Bio's soluble TNF mimic could treat ALS and PD by blocking inflammatory signaling that causes nerve cell death.
Published on 3/11/2013
-
Vedantra: Boosting T cell responses Vedantra Pharmaceuticals Inc. Cambridge, Mass. Technology: Structured lipid nanoparticles for co-delivery of vaccine and adjuvants Disease focus: Infectious Clinical status: …
Published on 3/4/2013
-
Vedantra has nanoparticle vaccine technology that is designed to generate a more potent antibody and T cell response than traditional subunit vaccines, initially targeting malaria and HPV.
Published on 3/4/2013
-
Longevity: Internal improvements Longevity Biotech Inc. Philadelphia, Pa. Technology: Peptidomimetics stabilized with non-natural beta amino acids Disease focus: Endocrine/metabolic, cardiovascular, cancer …
Published on 2/25/2013
-
Longevity Biotech is stabilizing peptides with internal non-natural beta amino acid modifications that minimize the risk of off-target binding and toxicity.
Published on 2/25/2013
-
Merganser is looking to tackle beta thalassemia using hepcidin peptides that can reduce the toxic accumulation of iron rather than mopping it up after the fact as marketed chelators do.
Published on 2/25/2013
-
Merganser: Hip to hep Merganser Biotech Inc. Newtown Square, Pa. Technology: Peptide mimetics of the iron regulatory hormone hepcidin Disease focus: Hematology Clinical status: Preclinical Founded: 2011 by Brian…
Published on 2/25/2013
-
Signum Dermalogix is targeting key inflammatory pathways to treat both symptoms and underlying mechanisms of rosacea.
Published on 2/18/2013
-
Signum: Rosacea double play Signum Dermalogix Inc. Monmouth Junction, N.J. Technology: Isoprenylcysteine analogs to treat inflammatory dermatological indications Disease focus: Dermatology Clinical status: …
Published on 2/18/2013
-
EnBiotix: Enhancing antibiotics EnBiotix Inc. Boston, Mass. Technology: Antibiotic potentiating compounds that increase reactive oxygen species or activate bacterial metabolism Disease focus: Infectious Clinical …
Published on 2/11/2013
-
EnBiotix is discovering compounds that make infections more susceptible to antibiotics by increasing the production of reactive oxygen species by bacteria or activating their metabolic pathways.
Published on 2/11/2013
-
GeneCentric: Cancer sign-off GeneCentric Durham, N.C. Technology: Molecular assays to stratify lung cancer subtypes and cancer patients likely to respond to anti-angiogenesis therapy Disease focus: Diagnostic …
Published on 2/11/2013
-
GeneCentric translates gene expression patterns into diagnostic tests for partners to market. It has launched its first test, an assay to subtype non-small cell lung cancer.
Published on 2/11/2013
-
Incanthera: Tumor targeting prodrugs Incanthera Ltd. Liverpool, U.K. Technology: Matrix metalloproteinase-activated prodrugs of vascular disrupting agents Disease focus: Cancer Clinical status: Preclinical …
Published on 2/4/2013
-
Incanthera is taking a new tack on matrix metalloproteinases, using them to activate cytotoxic cancer therapies at the tumor site.
Published on 2/4/2013